J Psychopharmacol
August 1, 2022
Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen et al.
73 citations
Depressive symptoms decreased two and four weeks after a psychedelic experience in a naturalistic, non-clinical setting. The study tracked a large group of people who planned to use psychedelics outside a lab or clinic, including only those with depressive symptoms at the start. A medicinal motive, prior psychedelic use, drug dose, and having an emotional breakthrough during the experience were all linked to greater symptom reductions. The authors note potential sample and attrition biases and call for further controlled and observational studies to confirm the findings.
Journal of Psychoactive Drugs
September 1, 2013
Robin Lester Carhart-Harris, David John Nutt
55 citations
Experienced drug users who have personally used 11 different illicit drugs rank alcohol and tobacco as the most harmful substances, while MDMA, LSD, psilocybin, and cannabis are ranked as the four least harmful. When asked about potential benefits, these same four drugs are ranked highest, and users cite therapeutic applications—such as tools to assist psychotherapy—rather than just pleasure. The findings offer insight from a rare sample of 93 users with intimate knowledge of multiple drugs.
Br J Clin Pharmacol
January 17, 2024
Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag et al.
7 citations
Lingering long COVID symptoms often severely impact daily life. A trial explored if a cannabidiol-dominant product offers a viable treatment. Participants experienced encouraging improvements in issues like pain, sleep, fatigue, and anxiety. This suggests a promising way to alleviate these symptoms and significantly boost overall quality of life for those affected by long COVID.